<![CDATA[Avutometinib/Defactinib Shows Activity in KRAS Wild-Type Recurrent LGSOC]]>

Data ReadoutpositiveavutometinibdefactinibPositive

AI Analysis

Summary

New analyses from the RAMP 201 trial showed that the combination of avutometinib and defactinib demonstrated activity in patients with KRAS wild-type recurrent low-grade serous ovarian cancer.

Clinical Trial Data

Outcome Details

Avutometinib plus defactinib demonstrated activity/responses in KRAS wild-type recurrent LGSOC

Importance:6/10

Sentiment:

0.70

oncologyovarian cancercombination therapyKRASclinical trial dataRAMP 201

Read the original article

Published by Cancer Network on October 6, 2026 4:30 PM

Read Original